Hot-melt%20co-extrusion%20technology%20as%20a%20manufacturing%20platform%20for%20anti-hypertensive%20fixed-dose%20combinations
Abstract

This work focused on the development of a concentric multi-layered fixed-dose combination via an advanced manufacturing technique, hot-melt co-extrusion. The dosage form was designed to offer differing release behaviour; immediate and sustained release from the coat and core, respectively. Hydrochlorothiazide and losartan potassium were incorporated as anti-hypertensive drugs. Solid-state characterisation revealed that both were transformed into their amorphous forms. In-vitro dissolution testing showed desired release performances offering both immediate and modified release.

Keywords

Fixed-dose combinations, hot-melt co-extrusion, hypertension

How to Cite
Almajaan A. , Healy A. , Jones D. , Gilvary G. , Andrews G. P. , Kelleher J. F. , Li S. , Tian Y. & Senta-Loys Z. (2019) “Hot-melt co-extrusion technology as a manufacturing platform for anti-hypertensive fixed-dose combinations”, British Journal of Pharmacy. 4(1). doi: https://doi.org/10.5920/bjpharm.596

61

Views

25

Downloads

Authors
Ammar Almajaan (Queen's University Belfast)
Anne-Marie Healy (Trinity College Dublin)

David Jones (Queen's University Belfast)

Gareth Colm Gilvary (Queen's University Belfast)

Gavin Paul Andrews (Queen's University Belfast)

Jeremiah Francis Kelleher (Trinity College Dublin)

Shu Li (Queen's University Belfast)

Yiwei Tian (Queen's University Belfast)

Zoe Senta-Loys (Queen's University Belfast)
Download
Dates
Licence

Creative Commons Attribution 4.0

Peer Review

This article has been peer reviewed.

File Checksums (MD5)
  • PDF: 91015fd36c68f3697887cba75ba4ce37